Pharmaceutical Industry Source Reduction Assessment
DTSC is preparing the first assessment of the California pharmaceutical industry’s efforts to reduce hazardous waste under the Hazardous Waste Source Reduction and Management Review Act of 1989 (SB 14). SB 14 requires DTSC to select two categories of generators by Standard Industrial Classification (SIC) code every two years for source reduction planning assessment. Selection of an industry is based on the consideration of several factors including the amount of waste generated, opportunity for source reduction measures and organizational interests focused on emerging issues. One of the industries selected in 2005 was the pharmaceutical industry. The pharmaceutical industry includes the manufacture, extraction, processing, purification, and packaging of chemical materials to be used as medications for humans or animals. Each of these production steps may generate air emissions, liquid effluents, and solid wastes. This assessment report focuses on the hazardous wastes generated by this industry.
cleaning/maintenance approaches take years to develop and receive final FDA approval. Changing these procedures requires supplemental FDA approval. This process can add a significant delay in the implementation of source reduction practices. Some source reduction opportunities exist when developing new products.
References and Related Publications
U.S. EPA, Profile of the Pharmaceutical Manufacturing Industry, EPA Office of Compliance Sector Notebook Project (EPA/310-R-97-005), September 1997
World Bank Group, Pharmaceuticals manufacturing-Pollution Prevention Abatement Handbook-World Bank Group, effective July 1998.